CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative